Skip to main content
SpringerLink
Log in

PrEP safe in adolescent MSM but compliance poor

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Adolescent Medicine Trials Network for HIV/AIDS Interventions 113

References

  1. Hosek SG et al. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA Pediatrics : 5 Sep 2017. Available from: URL: http://dx.doi.org/10.1001/jamapediatrics.2017.2007.

  2. Arrington-Sanders R. Human Immunodeficiency Virus Preexposure Prophylaxis for Adolescent Men. How Do We Ensure Health Equity for At-Risk Young Men? JAMA Pediatrics : 5 Sep 2017. Available from: URL: http://dx.doi.org/10.1001/jamapediatrics.2017.2397.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PrEP safe in adolescent MSM but compliance poor. PharmacoEcon Outcomes News 787, 32 (2017). https://doi.org/10.1007/s40274-017-4360-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4360-6

Search

Navigation